Traditional pipelines are almost running dry ! More than 95% of drug candidates fail during development, often after years of research and investments exceeding billions of dollars. The consequence is a shrinking and broken pipeline, escalating development costs, and delayed access to life-saving medicines. The challenge is not a lack of scientific innovation—it is the limitations of the current discovery model. Today's drug discovery process remains fragmented, sequential, and heavily dependent on trial-and-error. Data are generated in silos, biological complexity is insufficiently modelled, and critical decisions are often made too late in development, resulting in costly failures.

We believe drug discovery must evolve from an iterative process into an integrated, predictive, and engineering-driven discipline—one that combines advances in molecular biology, artificial intelligence, computational modelling, automation, and systems engineering to identify better therapeutic candidates earlier and with greater confidence.

Our mission is to transform drug discovery by developing technologies that reduce attrition, accelerate innovation, and improve the probability of clinical success. By redesigning the discovery pipeline from first principles, we aim to shorten development timelines, reduce costs, and deliver more effective medicines to patients.

The next generation of therapeutics will not emerge from doing the same process faster. It will come from building an entirely new discovery paradigm.Currently, no known systematic platform converts unutilized biological code into therapeutic assets.

The Quantum Codon platform is built as a fully integrated, end-to-end architecture that connects computational design with experimental validation. At its core, AI and quantum-inspired models explore vast, non-natural biological sequence spaces to generate novel proteins, peptides, and pathways. These designs flow into synthesis, high-throughput screening, and iterative learning loops, where experimental data continuously refine computational models. The platform is modular and scalable, enabling rapid deployment across therapeutics, diagnostics, and industrial biomanufacturing.

This closed-loop architecture transforms biology into an engineering discipline—accelerating discovery, reducing development timelines, and generating clean, first-principles intellectual property.

Our platform generates first-in-class molecules against high-value targets. Multiple therapeutic areas benefit from dark genome insights. Proof-of-the-concept exists in the following areas.